The difference between information and
expert, data-driven actionable intelligence
Welcome to the September 2016 issue of CMC Market Outlook
This monthly e-newsletter provides valuable insights for both buyers and sellers of CMC drug development services. Our coverage will help you identify and understand market trends that will inform your strategic business perspective.
Enjoy the September issue!
Innovation vs. Capacity: How CMOs Compete
by Jim Miller, President
While industry participants and observers talk about the “CMO industry,” they know that it is not an undifferentiated mass of manufacturers. The contract manufacturing organization (CMO) industry can be segmented along obvious lines such as API versus drug product manufacturers, biologics versus small molecule, dose form(s) manufactured, and geographic focus.
But none of these designations reflect the strategies that each CMO is pursuing, and without that basic understanding, one cannot fully understand the prospects for the industry… read on
Epirus Bankruptcy Underscores Biosimilar Challenges
by Saul Richmond, Director of Market Intelligence
The recent bankruptcy filing of Epirus Pharmaceuticals, an early stage company developing biosimilars, is a stark reminder of the risks inherent in biosimilar drug development. The company had previously shed 40% of its workforce and ceased late-stage development of its lead asset, a biosimilar version of Johnson & Johnson’s Remicade, but was attempting to maintain development of two smaller biosimilar opportunities, Soliris and Actermra. At the end of Q1 2016 the company reported cash-on-hand of $25 million but short-term liabilities of $32 million.
The Epirus bankruptcy followed on the heels of a chaotic IPO for another biosimilar developer, Oncobiologics, whose stock lost 20% on its first day of trading and has… read on
Will the dose CMO industry recover from a disappointing year?
Supply Chain Diversity Efforts Find Challenge in CMO Sector
Most global bio/pharmaceutical companies put a priority on diversity within their supply chains. Websites for many large companies-including Pfizer, Janssen, Bristol Myers Squibb, GlaxoSmithKline, AstraZeneca and Merck, for example-include pages dedicated to their supply diversity programs and emphasize the importance of diversity in their contracting activities.
However, bio/pharma companies find it challenging to find minority- or women-owned contract manufacturing organizations (CMOs) that can provide the full package of technological skills, regulatory savvy and proven reliability that they seek for contract service providers. Bio/pharma companies have not made… read on
PharmSource President Jim Miller to Speak at 2 Upcoming Events
Contract Pharma: 15th Annual Conference and Tabletop Exhibition.
New Brunswick, New Jersey
Thursday, September 22 at 2:00 pm
CPhI Worldwide: 8th Pre-Connect Congress.
Monday, October 3 at 10 am
Celebrating 20 Years in Business!
Thank you to our clients, colleagues and friends. We look forward to many more years of successful business together.
PharmSource Strategic Advantage
PharmSource’s STRATEGIC ADVANTAGE service is the industry’s most respected outsourcing information web portal for serious consumers of information on contract drug development and manufacturing. Developed from PharmSource’s expert proprietary research, you won’t find this information in any other resource.
See for yourself how this resource gives you vital tools for understanding the industry.
To request a test-drive today, contact Nathaniel Celentano at firstname.lastname@example.org / +1-703-383-4903, ext. 112 (ET USA).